Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease
Mediterranean diet may reduce chance of frailty, according to new study
27 June 2022How to get a vaccine against monkeypox in the US: Who should get one?
27 June 2022Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease
A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.
